Table 1.
Pre-clinical application of nanomaterials for cancer immunotherapy based on ICD.
Material | Application (therapy) | Experimental conditions | Therapeutic agents/adjuvant | Tumor model | Cell death type | Effect | Refs |
---|---|---|---|---|---|---|---|
Black phosphorus nanosheets | PTT | 60 µg/mL + 808 nm, 2W/cm2, 180 s | CpG | 4T1 | Necroptosis | CRT activation | (67) |
HMGB-1 release | |||||||
ATP secretion | |||||||
Raw 264.7 | ↑ Phagocytosis potential | ||||||
↑ TNFα | |||||||
↑ IL-6 | |||||||
2 mg/Kg + 808 nm, 2W/cm2, 1 min | Bilateral 4T1 xenografted Balb/c mice | Primary and secondary tumor regression | |||||
CD8+ T cells activation | |||||||
CD4+ T cells activation | |||||||
↓ Treg cells | |||||||
↑ TNFα | |||||||
↑ IL-2 | |||||||
↑ IFNɣ | |||||||
PFP@PEG-CMD-Ce6 Nanobubbles | US | 100 µg/mL + 300 s, power: 30 W, duty cycle: 20%, pulse repetition frequency: 1Hz, Y interval: 1mm | / | CT26 | RIPK3/MLKL independent necroptosis and apoptosis |
HMGB-1 release | (68) |
BMDCs | ↑ CD86+ | ||||||
On days 8, 11, 14, 1-3 mg Ce6/kg doses + time: 600 sec, power: 10 W, duty cycle: 20%, pulse repetition frequency: 1 Hz, Y interval: 1 mm | CT26 xenografted Balb/c mice | ↓ Tumor growth | |||||
PD-L1 100 µg/mouse |
↓↓ Tumor growth | ||||||
↓ Metastasis | |||||||
↑ CD8+ T cells infiltration | |||||||
Poly(lactic-co-glycolic acid) polymeric core-bearing breast cancer membrane biomimetic nanoparticle (BN) | NIR-photoactivation | 808 nm, 0.5 W/cm2, 2 min | Indocyanine green (ICG) 40 µg/mL + decitabine (DCT) 7.6 µg/mL | 4T1 | Pyroptosis and apoptosis | ↑ Ca2+ | (58) |
↑ Cyt c | |||||||
↑ caspase 3 | |||||||
↑ GSDME | |||||||
↑ N-terminal GSDME | |||||||
(4T1 + BN) + BMDCs | ↑ CD86+ | ||||||
↑ TNFα | |||||||
↑ IL-6 | |||||||
ICG 1 mg/kg + DCT 0.19 mg/kg | 4T1 xenografted Balb/c mice | ↑ caspase 3 | |||||
↑ N-terminal GSDME | |||||||
Bilateral 4T1 xenografted Balb/c mice | Primary and secondary tumor regression | ||||||
↑ TNFα | |||||||
↑ IL-6 | |||||||
↑ IFNɣ | |||||||
↑ DCs infiltration | |||||||
↑ CD8+ T cells infiltration | |||||||
↑ CD4+ T cells infiltration | |||||||
↓ Treg cells | |||||||
Nanoliposome | / | / | DAC pre-treatment (100 µL) + cisplatinum (80 µmol/L-1) | 4T1 xenografted Balb/c mice | Pyroptosis and apoptosis | ↓ Tumor growth | (69) |
↓ Metastasis | |||||||
↑ CD8+ T cells infiltration | |||||||
↑ DCs maturation | |||||||
Arginine-rich manganese silicate nanobubbles | / | 1 - 25 µg/mL | / | Huh7 | Ferroptosis | ↓ GSH; ↑ GSSG | (70) |
↓ GPX4 | |||||||
5 mg/kg | Huh7 xenografted Balb/c mice | ↓ Tumor growth | |||||
PEGylated single-atom Fe-containing nanocatalysts | / | 25 - 400 µg/mL | / | 4T1 | Ferroptosis and apoptosis | / | (43) |
20 mg/kg | 4T1 xenografted Balb/c mice | ↓ Tumor growth | |||||
NIR-photoactivation | 20 mg/kg; 808 nm, 1.5 W/cm2, 5 min | Complete tumor regression | |||||
Fe-doxorubicin preloaded amorphous CaCo3 nanoformulation | / | / | Doxorubicin 5 mg/kg + Fe2+ | 4T1 and A375 nude mice | Ferroptosis and apoptosis | ↓ Tumor growth No toxicity |
(71) |
↑ means "increase"; ↓ means "decrease".